{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009384","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.821809+00:00","generated_at":"2026-05-25T04:48:58.603761+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors","bullets":["Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.","Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.","Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.","Management will report a material weakness in internal controls over accrued royalty assessment.","Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009384","json":"https://secwatch.observer/filing/0001493152-25-009384.json","markdown":"https://secwatch.observer/filing/0001493152-25-009384.md","text":"https://secwatch.observer/filing/0001493152-25-009384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/0001493152-25-009384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T04:48:58.603761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}